thalidomide has been researched along with Glioma in 26 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 9.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "A phase II study was conducted to assess the efficacy of administering daily thalidomide concomitantly with radiation and continuing for up to 1 year following radiation in children with brain stem gliomas (BSG) or glioblastoma multiforme (GBM)." | 9.12 | Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. ( Briody, C; Chi, S; Chordas, C; Goumnerova, LC; Kieran, MW; MacDonald, T; Marcus, KJ; Packer, RJ; Poussaint, TY; Scott, RM; Turner, CD; Ullrich, N; Vajapeyam, S; Zimmerman, MA, 2007) |
| " Our data demonstrate that thalidomide in combination with BCNU is well tolerated and has antitumor activity in patients with recurrent high-grade gliomas." | 9.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas." | 9.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "The efficacy of thalidomide in terms of response in recurrent gliomas is low, with a partial response rate of only 6%." | 9.09 | Thalidomide as an anti-angiogenic agent in relapsed gliomas. ( Brada, M; Dowe, A; Gore, M; Hines, F; Short, SC; Traish, D, 2001) |
| "For its numerous abilities including sedation, we have been using thalidomide (TH) as the 'last therapeutic option' in patients with advanced gliomas." | 7.81 | Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. ( Ackerl, M; Dieckmann, KU; Flechl, B; Hainfellner, JA; Hassler, MR; Marosi, C; Prayer, D; Preusser, M; Rössler, K; Sax, C; Woehrer, A, 2015) |
| "Human malignant glioma cells U251-MG were cultured and assigned to four groups with different treatments for 3 days: temozolomide group (100 micromol/L), thalidomide group (100 microg/L), temozolomide (100 micromol/L) plus thalidomide group (100 microg/L) and control group." | 7.75 | Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. ( Gao, S; Ji, YW; Pan, Q; Yang, XJ; Zhang, WG, 2009) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 7.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "Serial MR imaging was performed in 18 consecutive patients with recurrent malignant gliomas receiving both thalidomide and carboplatin for 12-month periods." | 7.70 | Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. ( Cha, S; Glass, J; Gruber, ML; Johnson, G; Knopp, EA; Litt, A; Lu, S; Zagzag, D, 2000) |
| "Malignant gliomas are tumors with a very unfavorable prognosis." | 5.43 | Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas. ( Kramm, CM; Kühnöl, CD; Staege, MS, 2016) |
| "Gliomas are highly vascularized tumors, suggesting that the prevention of vessel formation by anti-angiogenic treatment might be effective." | 5.40 | Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. ( Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D, 2014) |
| "Thalidomide treatment also dramatically suppressed the anchorage-independent growth of U-87 MG and other glioma cells by over a thousand fold without affecting its anchorage-dependent growth, which may be accomplished by knocking down endogenous bFGF expression in these cells." | 5.35 | The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. ( Mei, SC; Wu, RT, 2008) |
| "Thalidomide is a racemate with known pharmacologic and pharmacokinetic enantioselectivity." | 5.34 | Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. ( Boyle, FM; Davey, RA; Gu, XQ; Mather, LE; Murphy, S, 2007) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 5.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 5.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "A phase II study was conducted to assess the efficacy of administering daily thalidomide concomitantly with radiation and continuing for up to 1 year following radiation in children with brain stem gliomas (BSG) or glioblastoma multiforme (GBM)." | 5.12 | Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. ( Briody, C; Chi, S; Chordas, C; Goumnerova, LC; Kieran, MW; MacDonald, T; Marcus, KJ; Packer, RJ; Poussaint, TY; Scott, RM; Turner, CD; Ullrich, N; Vajapeyam, S; Zimmerman, MA, 2007) |
| " Our data demonstrate that thalidomide in combination with BCNU is well tolerated and has antitumor activity in patients with recurrent high-grade gliomas." | 5.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas." | 5.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "The efficacy of thalidomide in terms of response in recurrent gliomas is low, with a partial response rate of only 6%." | 5.09 | Thalidomide as an anti-angiogenic agent in relapsed gliomas. ( Brada, M; Dowe, A; Gore, M; Hines, F; Short, SC; Traish, D, 2001) |
| "For its numerous abilities including sedation, we have been using thalidomide (TH) as the 'last therapeutic option' in patients with advanced gliomas." | 3.81 | Thalidomide as palliative treatment in patients with advanced secondary glioblastoma. ( Ackerl, M; Dieckmann, KU; Flechl, B; Hainfellner, JA; Hassler, MR; Marosi, C; Prayer, D; Preusser, M; Rössler, K; Sax, C; Woehrer, A, 2015) |
| "Human malignant glioma cells U251-MG were cultured and assigned to four groups with different treatments for 3 days: temozolomide group (100 micromol/L), thalidomide group (100 microg/L), temozolomide (100 micromol/L) plus thalidomide group (100 microg/L) and control group." | 3.75 | Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. ( Gao, S; Ji, YW; Pan, Q; Yang, XJ; Zhang, WG, 2009) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 3.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "Serial MR imaging was performed in 18 consecutive patients with recurrent malignant gliomas receiving both thalidomide and carboplatin for 12-month periods." | 3.70 | Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. ( Cha, S; Glass, J; Gruber, ML; Johnson, G; Knopp, EA; Litt, A; Lu, S; Zagzag, D, 2000) |
| "Malignant gliomas are tumors with a very unfavorable prognosis." | 1.43 | Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas. ( Kramm, CM; Kühnöl, CD; Staege, MS, 2016) |
| "Gliomas are highly vascularized tumors, suggesting that the prevention of vessel formation by anti-angiogenic treatment might be effective." | 1.40 | Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma. ( Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D, 2014) |
| "Thalidomide treatment also dramatically suppressed the anchorage-independent growth of U-87 MG and other glioma cells by over a thousand fold without affecting its anchorage-dependent growth, which may be accomplished by knocking down endogenous bFGF expression in these cells." | 1.35 | The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. ( Mei, SC; Wu, RT, 2008) |
| "Thalidomide is a racemate with known pharmacologic and pharmacokinetic enantioselectivity." | 1.34 | Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. ( Boyle, FM; Davey, RA; Gu, XQ; Mather, LE; Murphy, S, 2007) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 1.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Thalidomide has been previously shown to inhibit angiogenesis induced by basic fibroblast growth factor in vivo, using the rabbit corneal micropocket assay." | 1.30 | Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. ( Friedlander, DR; Kaplan, G; Moreira, AL; Shif, B; Zagzag, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 13 (50.00) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yung, R | 1 |
| Seyfoddin, V | 1 |
| Guise, C | 1 |
| Tijono, S | 1 |
| McGregor, A | 1 |
| Connor, B | 1 |
| Ching, LM | 1 |
| Porkholm, M | 1 |
| Valanne, L | 2 |
| Lönnqvist, T | 2 |
| Holm, S | 1 |
| Lannering, B | 1 |
| Riikonen, P | 2 |
| Wojcik, D | 1 |
| Sehested, A | 1 |
| Clausen, N | 1 |
| Harila-Saari, A | 1 |
| Schomerus, E | 1 |
| Thorarinsdottir, HK | 1 |
| Lähteenmäki, P | 1 |
| Arola, M | 1 |
| Thomassen, H | 1 |
| Saarinen-Pihkala, UM | 2 |
| Kivivuori, SM | 2 |
| Hassler, MR | 1 |
| Sax, C | 1 |
| Flechl, B | 1 |
| Ackerl, M | 1 |
| Preusser, M | 1 |
| Hainfellner, JA | 1 |
| Woehrer, A | 1 |
| Dieckmann, KU | 1 |
| Rössler, K | 1 |
| Prayer, D | 1 |
| Marosi, C | 1 |
| Milanovic, D | 1 |
| Sticht, C | 1 |
| Röhrich, M | 1 |
| Maier, P | 1 |
| Grosu, AL | 1 |
| Herskind, C | 1 |
| Kuramitsu, S | 1 |
| Ohno, M | 1 |
| Ohka, F | 1 |
| Shiina, S | 1 |
| Yamamichi, A | 1 |
| Kato, A | 1 |
| Tanahashi, K | 1 |
| Motomura, K | 1 |
| Kondo, G | 1 |
| Kurimoto, M | 1 |
| Senga, T | 1 |
| Wakabayashi, T | 1 |
| Natsume, A | 1 |
| Kühnöl, CD | 1 |
| Staege, MS | 1 |
| Kramm, CM | 1 |
| Shimizu, T | 1 |
| Kurozumi, K | 2 |
| Ishida, J | 1 |
| Ichikawa, T | 2 |
| Date, I | 2 |
| Mei, SC | 1 |
| Wu, RT | 1 |
| Gao, S | 1 |
| Yang, XJ | 1 |
| Zhang, WG | 1 |
| Ji, YW | 1 |
| Pan, Q | 1 |
| Onishi, M | 1 |
| Ruiz, J | 1 |
| Case, D | 1 |
| Enevold, G | 1 |
| Rosdhal, R | 1 |
| Tatter, SB | 1 |
| Ellis, TL | 1 |
| McQuellon, RP | 1 |
| McMullen, KP | 1 |
| Stieber, VW | 1 |
| Shaw, EG | 1 |
| Lesser, GJ | 1 |
| Giglio, P | 1 |
| Dhamne, M | 1 |
| Hess, KR | 1 |
| Gilbert, MR | 1 |
| Groves, MD | 1 |
| Levin, VA | 2 |
| Kang, SL | 1 |
| Ictech, SE | 1 |
| Liu, V | 1 |
| Colman, H | 1 |
| Conrad, CA | 1 |
| Loghin, M | 1 |
| de Groot, J | 1 |
| Yung, WK | 2 |
| Puduvalli, VK | 1 |
| Fine, HA | 2 |
| Wen, PY | 3 |
| Maher, EA | 1 |
| Viscosi, E | 1 |
| Batchelor, T | 1 |
| Lakhani, N | 1 |
| Figg, WD | 2 |
| Purow, BW | 1 |
| Borkowf, CB | 1 |
| Takano, S | 1 |
| Son, MJ | 1 |
| Kim, JS | 1 |
| Kim, MH | 1 |
| Song, HS | 1 |
| Kim, JT | 2 |
| Kim, H | 1 |
| Shin, T | 1 |
| Jeon, HJ | 1 |
| Lee, DS | 1 |
| Park, SY | 1 |
| Kim, YJ | 1 |
| Kim, JH | 1 |
| Nam, DH | 2 |
| Lee, JI | 1 |
| Itasaka, S | 1 |
| Turner, CD | 1 |
| Chi, S | 1 |
| Marcus, KJ | 1 |
| MacDonald, T | 1 |
| Packer, RJ | 1 |
| Poussaint, TY | 1 |
| Vajapeyam, S | 1 |
| Ullrich, N | 1 |
| Goumnerova, LC | 1 |
| Scott, RM | 1 |
| Briody, C | 1 |
| Chordas, C | 1 |
| Zimmerman, MA | 1 |
| Kieran, MW | 1 |
| Murphy, S | 1 |
| Boyle, FM | 1 |
| Davey, RA | 1 |
| Gu, XQ | 1 |
| Mather, LE | 1 |
| Kesari, S | 1 |
| Schiff, D | 1 |
| Doherty, L | 1 |
| Gigas, DC | 1 |
| Batchelor, TT | 1 |
| Muzikansky, A | 1 |
| O'Neill, A | 1 |
| Drappatz, J | 1 |
| Chen-Plotkin, AS | 1 |
| Ramakrishna, N | 1 |
| Weiss, SE | 1 |
| Levy, B | 1 |
| Bradshaw, J | 1 |
| Kracher, J | 1 |
| Laforme, A | 1 |
| Black, PM | 2 |
| Folkman, J | 1 |
| Kieran, M | 1 |
| Burton, E | 1 |
| Prados, M | 1 |
| Moreira, AL | 1 |
| Friedlander, DR | 1 |
| Shif, B | 1 |
| Kaplan, G | 1 |
| Zagzag, D | 2 |
| Jaeckle, K | 1 |
| Kyritsis, AP | 1 |
| Loeffler, JS | 1 |
| Kaplan, R | 1 |
| Pluda, JM | 1 |
| Cha, S | 1 |
| Knopp, EA | 1 |
| Johnson, G | 1 |
| Litt, A | 1 |
| Glass, J | 1 |
| Gruber, ML | 1 |
| Lu, S | 1 |
| Cohen, MH | 1 |
| Short, SC | 1 |
| Traish, D | 1 |
| Dowe, A | 1 |
| Hines, F | 1 |
| Gore, M | 1 |
| Brada, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas[NCT00047879] | Phase 2 | 7 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00047879)
Timeframe: 4 months
| Intervention | Participants (Number) |
|---|---|
| Glioblastoma Multiforme Stratum | 4 |
| Anaplastic Glioma Stratum | 2 |
4 reviews available for thalidomide and Glioma
| Article | Year |
|---|---|
Adhesion molecules and the extracellular matrix as drug targets for glioma.
Topics: Angiogenesis Inhibitors; Antibodies; Brain Neoplasms; Cell Adhesion Molecules; Disease Progression; | 2016 |
Angiogenesis and invasion in glioma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevaciz | 2011 |
[Anti-angiogenesis treatment for brain tumors--present and future].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Tr | 2005 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
7 trials available for thalidomide and Glioma
| Article | Year |
|---|---|
A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Female; Follow-Up Studies; G | 2012 |
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; | 2012 |
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2003 |
Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme.
Topics: Adolescent; Angiogenesis Inhibitors; Brain Stem Neoplasms; Child; Combined Modality Therapy; Disease | 2007 |
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2007 |
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality T | 2000 |
Thalidomide as an anti-angiogenic agent in relapsed gliomas.
Topics: Adult; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Glioma; Humans; Middle Aged; N | 2001 |
15 other studies available for thalidomide and Glioma
| Article | Year |
|---|---|
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Mode | 2014 |
Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Case-Control Studi | 2014 |
Thalidomide as palliative treatment in patients with advanced secondary glioblastoma.
Topics: Adult; Antineoplastic Agents; Female; Glioblastoma; Glioma; Humans; Male; Palliative Care; Retrospec | 2015 |
Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2015 |
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Glioma; Humans; Immunologic Fa | 2015 |
Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas.
Topics: Antineoplastic Agents; Dendritic Cells; Drug Screening Assays, Antitumor; Glioma; Humans; Immunologi | 2016 |
The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma.
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Fibroblast Growth Factor 2; Glioma; Guanine; Humans; Promo | 2008 |
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gli | 2009 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neop | 2011 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 2007 |
Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro.
Topics: Animals; Cell Division; Cornea; Endothelium, Vascular; Fibroblast Growth Factor 2; Glioma; Humans; N | 1999 |
Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Echo-Plan | 2000 |
Thalidomide in the treatment of high-grade gliomas.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase II as Topic; Glioma; Humans; Middle Aged; Thalidomid | 2000 |